Developer docs
API playgroundTry for free, no card

Search company profiles

Boyds

Full company profile

uuid000nwp1

Namestring
Boyds
Legal namestring
Boyds International Life Sciences Group Limited
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Boyds is a UK-headquartered drug development consultancy founded in 2005 by Professor Alan Boyd, operating as Boyds International Life Sciences Group Limited (registered in England and Wales). The firm provides integrated regulatory affairs, clinical and medical affairs, clinical operations, pharmaceutical due diligence, product development, and medical device consulting services to pharmaceutical companies, biotechs, medical device firms, and universities across the US, UK, and Europe. Its differentiation centres on advanced therapies (cell and gene therapies, ATMPs, orphan drugs) with documented support for multiple approved cell and gene therapies, 20+ years of regulatory experience working with FDA, EMA, and MHRA, and official EMA SME status enabling client fee reductions of up to 90%. The firm has been recognised with the Queen's Award for Enterprise (International Trade, 2018) and the TOPRA Award for Regulatory Excellence (2023).

Core capabilities are delivered through a team of experienced pharmaceutical physicians and regulatory experts, including senior leaders with prior experience at Pfizer, Merck, Astellas Pharma, Ferring Pharmaceuticals, and the MHRA's predecessor organisation. Underpinning technology infrastructure includes the LORENZ docuBridge regulatory information management system for eCTD publishing, electronic submissions, and regulatory document management. The firm also operates dedicated service lines such as 'B-Investor Ready' for early-stage biotech fundraising preparation, 'My Development TEAM' for fractional development team outsourcing, interim CMO support, and a thought leadership podcast ('Conversations in Drug Development').

The business model is professional services-based, generating revenue through project-based engagements, multi-year retainers, and interim staffing solutions. Pricing is custom and quote-based, varying by scope, team composition, and duration. The go-to-market motion is sales-led via direct outreach, supplemented by thought leadership content (podcasts, webinars, blog, case studies), industry events and conferences, and LinkedIn-driven engagement. The company is founder-led and privately held with no external funding rounds disclosed, growing organically across its four offices in Crewe (HQ), Cambridge, Pennsylvania, and Dublin.

Short descriptiontext

Boyds is a UK-headquartered drug development consultancy founded in 2005 that provides regulatory affairs, clinical operations, medical affairs, and product development services to pharmaceutical, biotech, and medical device companies globally, with particular specialisation in advanced therapies and cell and gene therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCrewe, United Kingdom
HQ citystring
Crewe
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs consulting, clinical operations services, drug development consultancy, pharmaceutical due diligence, medical device consulting
Industry2 codes
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Other Scientific and Technical Consulting Services54169
  • Management, Scientific, and Technical Consulting Services5416
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Engineering, Accounting, Research, Management8700
Product category
Pharmaceutical Regulatory & Drug Development Consulting
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Consulting Services
TypeProfessional Services
Description

Boyds generates revenue through providing expert consultancy services across regulatory affairs, clinical operations, medical affairs, product development, and due diligence. Services are delivered through project-based engagements, retainers, and interim staffing solutions.

boydconsultants.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Custom consulting engagements
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is project-specific and quote-based, varying based on scope of work, team composition, and engagement duration.

boydconsultants.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1B-Investor Ready
Description

A service offered by Boyds to help early-stage biotech companies prepare for investor readiness and secure funding.

boydconsultants.com
+2 more records
Core offering1 text field

Boyds is a global drug development consultancy that translates innovative scientific ideas into approved medicinal products. It provides expert consulting across regulatory affairs (FDA, EMA, MHRA submissions), clinical operations and biostatistics, medical affairs and interim CMO support, product development, pharmaceutical due diligence, CMC regulatory affairs, regulatory operations and publishing, and medical device consulting. The firm serves pharmaceutical, biotechnology, and medical device companies with particular depth in advanced therapies, cell and gene therapies, ATMPs, rare diseases, and oncology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 95%+ client satisfaction rate
+1 more record
Product overview1 text field

Boyds is a global drug development consultancy that translates innovative ideas into medicinal products and treatments for patient benefit. Founded in 2005 by Professor Alan Boyd MBE, the firm operates as a unified consultancy offering integrated services rather than a software platform with discrete products. The service portfolio centers on Regulatory Affairs Consulting (covering FDA, EMA, MHRA filings), Clinical and Medical Affairs (medical monitoring, interim CMO support, scientific advice), Clinical Operations (biostatistics, project management, site monitoring, study start-up), Product Development (including Investor Readiness via B-Investor Ready, fractional CDO services), Regulatory Operations and Publishing (eCTD submissions, collaborative pathways like Project Orbis), Pharmaceutical Due Diligence, Early Access Programs with Real-World Data Collection, and Medical Device Consulting. The company also produces educational content through its 'Conversations in Drug Development' podcast. Boyds specializes in advanced therapies including cell and gene therapies, small molecules, biologics, and orphan drugs, with expertise across oncology, rare diseases, and ATMPs. Key differentiators include award-winning regulatory affairs (Queen's Award 2018, TOPRA Futures Award 2023), EMA SME status for client fee benefits, and dual presence across US, UK, and Ireland offices.

Product and service1 record
1Regulatory Affairs Consulting
CategoryRegulatory Affairs Consulting
Description

Strategic and hands-on regulatory support across the full drug development lifecycle, working with FDA, EMA, MHRA, and global regulatory agencies to facilitate efficient development and approval of medicinal products. Targeted at pharmaceutical and biotechnology companies seeking expert regulatory strategy.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1MIAS Pharma
Strategic tierMinorTypeOthers
Description

Listed as a partner in the Resources section. MIAS Pharma is a pharmaceutical industry partner providing regulatory and consulting services.

boydconsultants.com
Strategic tierMinorTypeOthers
Description

Listed as a partner in the Resources section. Stratagem is an intellectual property management partner.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner in the Resources section. TherapeutAix is a strategic partner in therapeutics development.

4LORENZ docuBridge
Strategic tierCoreTypeTechnology or Integration
Description

Boyds has invested in the industry-leading regulatory information management system, LORENZ docuBridge, to enable full electronic submission, publishing, and regulatory document management. This is a core technology partnership for their regulatory operations services.

boydconsultants.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major global CRO with deep regulatory affairs and drug development consulting capabilities across pharma and biotech. Overlapping service scope with Boyds but at significantly larger scale and broader geographic reach.

TypeDirect peer
Description

Clinical research organisation specialising in early-phase clinical research and bioanalytical services. Comparable for early-stage drug development engagements, particularly for biotech clients running first-in-human studies.

TypeBroad incumbent
Description

Large, established CRO/CDMO offering preclinical, clinical and manufacturing services across pharma and biotech. Overlaps with Boyds in early-stage drug development and regulatory affairs support, but as part of a much wider portfolio.

TypeDirect peer
Description

Mid-size global CRO providing clinical trial services including regulatory affairs, biostatistics and medical affairs across pharma and biotech. Direct competitor for clinical operations and regulatory consulting engagements.

TypeDirect peer
Description

Mid-size CRO offering regulatory, clinical operations and biometrics services to biotech and pharma. Closely comparable in scale and service breadth to Boyds' clinical operations and biostatistics offerings.

TypeDirect peer
Description

Germany-based regulatory affairs, pharmacovigilance and quality consulting firm serving pharma, biotech and medical device companies. Directly comparable service portfolio (regulatory strategy, submissions, CMC) and similar mid-market positioning to Boyds.

TypeBroad incumbent
Description

Larger CRO/contract laboratory offering CMC, bioanalytical, preclinical and clinical services to pharma and biotech. Broader and more scaled than Boyds but overlapping in CMC regulatory affairs and drug development support.

TypeBroad incumbent
Description

Top-tier global CRO providing clinical, regulatory, laboratory and consulting services across all phases of drug development. Overlaps with Boyds' clinical operations and regulatory consulting, but at vastly greater scale.

TypeDirect peer
Description

US-headquartered regulatory, compliance, clinical and quality consulting organisation serving pharma and biotech. Highly comparable in scope of regulatory and drug development consulting services, with broader scale than Boyds.

TypeDirect peer
Description

Sweden-headquartered regulatory and pharmacovigilance consultancy serving pharma and biotech globally. The closest functional peer to Boyds — similar size, similar regulatory-affairs-and-drug-development focus, and overlapping client segments in early-stage biotech and ATMP developers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Boyds

Pharmaceutical Regulatory & Drug Development Consultingboydconsultants.com

Boyds is a UK-headquartered drug development consultancy founded in 2005 that provides regulatory affairs, clinical operations, medical affairs, and product development services to pharmaceutical, biotech, and medical device companies globally, with particular specialisation in advanced therapies and cell and gene therapies.

What Boyds does

Boyds is a UK-headquartered drug development consultancy founded in 2005 by Professor Alan Boyd, operating as Boyds International Life Sciences Group Limited (registered in England and Wales). The firm provides integrated regulatory affairs, clinical and medical affairs, clinical operations, pharmaceutical due diligence, product development, and medical device consulting services to pharmaceutical companies, biotechs, medical device firms, and universities across the US, UK, and Europe. Its differentiation centres on advanced therapies (cell and gene therapies, ATMPs, orphan drugs) with documented support for multiple approved cell and gene therapies, 20+ years of regulatory experience working with FDA, EMA, and MHRA, and official EMA SME status enabling client fee reductions of up to 90%. The firm has been recognised with the Queen's Award for Enterprise (International Trade, 2018) and the TOPRA Award for Regulatory Excellence (2023).

Core capabilities are delivered through a team of experienced pharmaceutical physicians and regulatory experts, including senior leaders with prior experience at Pfizer, Merck, Astellas Pharma, Ferring Pharmaceuticals, and the MHRA's predecessor organisation. Underpinning technology infrastructure includes the LORENZ docuBridge regulatory information management system for eCTD publishing, electronic submissions, and regulatory document management. The firm also operates dedicated service lines such as 'B-Investor Ready' for early-stage biotech fundraising preparation, 'My Development TEAM' for fractional development team outsourcing, interim CMO support, and a thought leadership podcast ('Conversations in Drug Development').

The business model is professional services-based, generating revenue through project-based engagements, multi-year retainers, and interim staffing solutions. Pricing is custom and quote-based, varying by scope, team composition, and duration. The go-to-market motion is sales-led via direct outreach, supplemented by thought leadership content (podcasts, webinars, blog, case studies), industry events and conferences, and LinkedIn-driven engagement. The company is founder-led and privately held with no external funding rounds disclosed, growing organically across its four offices in Crewe (HQ), Cambridge, Pennsylvania, and Dublin.

Boyds firmographics

Firmographics
Name
Boyds
Legal name
Boyds International Life Sciences Group Limited
Website
https://boydconsultants.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Boyds is a UK-headquartered drug development consultancy founded in 2005 that provides regulatory affairs, clinical operations, medical affairs, and product development services to pharmaceutical, biotech, and medical device companies globally, with particular specialisation in advanced therapies and cell and gene therapies.
Ownership category
akta.pro rank

Boyds industry classification

Industry
Product category
Pharmaceutical Regulatory & Drug Development Consulting
NAICS
Other Scientific and Technical Consulting Services (54169), Management, Scientific, and Technical Consulting Services (5416), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700)
akta.pro industry
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Regulatory affairs consulting
  • Clinical operations services
  • Drug development consultancy
  • Pharmaceutical due diligence
  • Medical device consulting

Where Boyds is headquartered

Location

Headquarters

HQ city
Crewe
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Boyds business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Consulting Services: Boyds generates revenue through providing expert consultancy services across regulatory affairs, clinical operations, medical affairs, product development, and due diligence. Services are delivered through project-based engagements, retainers, and interim staffing solutions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom consulting engagements

Go-to-market motion2 records

Distribution channels1 record

Marketing channels9 records

Boyds product offering

Product offering

Core offering

Boyds is a global drug development consultancy that translates innovative scientific ideas into approved medicinal products. It provides expert consulting across regulatory affairs (FDA, EMA, MHRA submissions), clinical operations and biostatistics, medical affairs and interim CMO support, product development, pharmaceutical due diligence, CMC regulatory affairs, regulatory operations and publishing, and medical device consulting. The firm serves pharmaceutical, biotechnology, and medical device companies with particular depth in advanced therapies, cell and gene therapies, ATMPs, rare diseases, and oncology.

Product overview

Boyds is a global drug development consultancy that translates innovative ideas into medicinal products and treatments for patient benefit. Founded in 2005 by Professor Alan Boyd MBE, the firm operates as a unified consultancy offering integrated services rather than a software platform with discrete products. The service portfolio centers on Regulatory Affairs Consulting (covering FDA, EMA, MHRA filings), Clinical and Medical Affairs (medical monitoring, interim CMO support, scientific advice), Clinical Operations (biostatistics, project management, site monitoring, study start-up), Product Development (including Investor Readiness via B-Investor Ready, fractional CDO services), Regulatory Operations and Publishing (eCTD submissions, collaborative pathways like Project Orbis), Pharmaceutical Due Diligence, Early Access Programs with Real-World Data Collection, and Medical Device Consulting. The company also produces educational content through its 'Conversations in Drug Development' podcast. Boyds specializes in advanced therapies including cell and gene therapies, small molecules, biologics, and orphan drugs, with expertise across oncology, rare diseases, and ATMPs. Key differentiators include award-winning regulatory affairs (Queen's Award 2018, TOPRA Futures Award 2023), EMA SME status for client fee benefits, and dual presence across US, UK, and Ireland offices.

Differentiator

Problem solved

Functional benefit

Brands

  • B-Investor Ready: A service offered by Boyds to help early-stage biotech companies prepare for investor readiness and secure funding.
  • My Development TEAM
  • Conversations in Drug Development

Products and services

  • Regulatory Affairs Consulting Strategic and hands-on regulatory support across the full drug development lifecycle, working with FDA, EMA, MHRA, and global regulatory agencies to facilitate efficient development and approval of medicinal products. Targeted at pharmaceutical and biotechnology companies seeking expert regulatory strategy.

Quantifiable outcome

  • 95%+ client satisfaction rate
  • +1 more outcomes

Companies that use Boyds

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles4 records

Boyds technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Boyds partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • MIAS PharmaminorOthersListed as a partner in the Resources section. MIAS Pharma is a pharmaceutical industry partner providing regulatory and consulting services.
  • StratagemminorOthersListed as a partner in the Resources section. Stratagem is an intellectual property management partner.
  • TherapeutAixminorStrategic or Co-development PartnerListed as a partner in the Resources section. TherapeutAix is a strategic partner in therapeutics development.
  • LORENZ docuBridgecoreTechnology or IntegrationBoyds has invested in the industry-leading regulatory information management system, LORENZ docuBridge, to enable full electronic submission, publishing, and regulatory document management. This is a core technology partnership for their regulatory operations services.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Boyds competitors and assessment

Company assessment

Broad incumbents

  • Parexel International: Major global CRO with deep regulatory affairs and drug development consulting capabilities across pharma and biotech. Overlapping service scope with Boyds but at significantly larger scale and broader geographic reach.
  • Charles River Laboratories: Large, established CRO/CDMO offering preclinical, clinical and manufacturing services across pharma and biotech. Overlaps with Boyds in early-stage drug development and regulatory affairs support, but as part of a much wider portfolio.
  • Frontage Laboratories: Larger CRO/contract laboratory offering CMC, bioanalytical, preclinical and clinical services to pharma and biotech. Broader and more scaled than Boyds but overlapping in CMC regulatory affairs and drug development support.
  • ICON plc: Top-tier global CRO providing clinical, regulatory, laboratory and consulting services across all phases of drug development. Overlaps with Boyds' clinical operations and regulatory consulting, but at vastly greater scale.

Direct peers

  • Celerion: Clinical research organisation specialising in early-phase clinical research and bioanalytical services. Comparable for early-stage drug development engagements, particularly for biotech clients running first-in-human studies.
  • Worldwide Clinical Trials: Mid-size global CRO providing clinical trial services including regulatory affairs, biostatistics and medical affairs across pharma and biotech. Direct competitor for clinical operations and regulatory consulting engagements.
  • Clinipace Worldwide (now dMed): Mid-size CRO offering regulatory, clinical operations and biometrics services to biotech and pharma. Closely comparable in scale and service breadth to Boyds' clinical operations and biostatistics offerings.
  • Pharmalex: Germany-based regulatory affairs, pharmacovigilance and quality consulting firm serving pharma, biotech and medical device companies. Directly comparable service portfolio (regulatory strategy, submissions, CMC) and similar mid-market positioning to Boyds.
  • ProPharma Group: US-headquartered regulatory, compliance, clinical and quality consulting organisation serving pharma and biotech. Highly comparable in scope of regulatory and drug development consulting services, with broader scale than Boyds.
  • NDA Group: Sweden-headquartered regulatory and pharmacovigilance consultancy serving pharma and biotech globally. The closest functional peer to Boyds — similar size, similar regulatory-affairs-and-drug-development focus, and overlapping client segments in early-stage biotech and ATMP developers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Boyds social profiles

Digital presence

Boyds compliance and trust

Trust signal

Compliance4 records

Boyds financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Boyds leadership team

Management profile

Number of profiles

Profiles9 records

Boyds funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Boyds M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boyds

What does Boyds do?

Boyds is a global drug development consultancy that translates innovative scientific ideas into approved medicinal products. It provides expert consulting across regulatory affairs (FDA, EMA, MHRA submissions), clinical operations and biostatistics, medical affairs and interim CMO support, product development, pharmaceutical due diligence, CMC regulatory affairs, regulatory operations and publishing, and medical device consulting. The firm serves pharmaceutical, biotechnology, and medical device companies with particular depth in advanced therapies, cell and gene therapies, ATMPs, rare diseases, and oncology.

Is Boyds a public or private company?

Boyds is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Boyds founded?

Boyds was founded in 2005. It employs 51 to 100 people.

Where is Boyds based?

Boyds is headquartered in Crewe, United Kingdom, in the Europe region.

How does Boyds make money?

One revenue line is on record: consulting Services.

Who are Boyds's main competitors?

Broad incumbents on record are Parexel International, Charles River Laboratories, Frontage Laboratories and ICON plc. Direct peers are Celerion, Worldwide Clinical Trials, Clinipace Worldwide (now dMed), Pharmalex, ProPharma Group and NDA Group.

Does Boyds have an API?

No public API is recorded for Boyds.

What industry is Boyds in?

Boyds's product category is Pharmaceutical Regulatory & Drug Development Consulting. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BdailyBoyds appoints chief medical officerBoyds, a global drug development consultancy headquartered in Crewe, UK, has appointed Laurence Skillern as chief medical officer to strengthen its senior leadership team and expand its medical and clinical expertise. Laurence brings experience from senior roles at Pfizer, Merck, Astellas Pharma, Ferring Pharmaceuticals, and Freya Biosciences, as well as regulatory experience at MHRA's predecessor organisation. His appointment reflects Boyds' continued investment in senior scientific leadership to meet increased demand for medical and pharmaceutical physician expertise among its pharmaceutical and biotechnology clients.The Medicine MakerManufacturability and the Winners in Advanced TherapiesAlan Boyd, founder and CEO of consultancy firm Boyds, discusses in an interview how manufacturing has replaced discovery as the rate-limiting step in advanced therapies, noting that living medicines are harder to produce at scale than traditional chemical entities. He highlights that securing funding in the cell and gene therapy sector has become increasingly difficult over the past two to three years, with the UK leading in Europe for life sciences investment while the US continues to dominate globally. The interview explores broader industry trends, including a resurgence in small molecule development and the need to reduce manufacturing costs to make transformative therapies more accessible to larger patient populations.The Philadelphia InquirerBoyds opens permanent store outside Philly for first time in 84 yearsBoyds opened its first permanent store outside Philadelphia in Wayne in September, after a pop-up in 2020 following civil unrest damage. The 10,000-square-foot store is one-third the size of the downtown flagship, with women's fashion accounting for about one-third of revenue. Owner Kent Gushner said he wants to help improve the city's safety.